Merck publishes interim results from Ph III trials of Keytruda® (pembrolizumab) in melanoma

Mar 7, 2022

Merck published interim results from its Ph III trial of Keytruda® (pembrolizumab) as an adjuvant treatment for patients with stage IIB and IIC melanoma.  According to the announcement, the trial met its key secondary endpoint and showed an improvement in recurrent-free survival compared to placebo.

Print Page Mail Article